Загрузка...
Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts
Many current pharmaceutical therapies for systolic heart failure target intracellular [Ca(2+)] ([Ca(2+)](i)) metabolism, or cardiac troponin C (cTnC) on thin filaments, and can have significant side-effects, including arrhythmias or adverse effects on diastolic function. In this study, we tested the...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4082830/ https://ncbi.nlm.nih.gov/pubmed/24690333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yjmcc.2014.03.015 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|